Market Overview

UPDATE: JP Morgan Raises PT to $62 on Health Care REIT Post Q2

Related HCN
BMO Capital's John Kim Explains Why Ventas Is A Healthcare REIT Worth Watching
Buy Healthcare REITs, It's The Best Time To Do It In 18 Months: Canaccord
My Third Quarter 2015 Portfolio Review - Doing Some Buying (Seeking Alpha)

JP Morgan reiterated its Overweight rating on Health Care REIT (NYSE: HCN) and increased its price target from $61 to $62.

JP Morgan commented, "Our OW rating on HCN is based on a number of factors including our belief that the stock has above-average growth prospects relative to the health care sector, and we see valuation attractive based on discounted trading multiples and an above-average dividend yield."

Health Care REIT closed at $60.17 on Thursday.

Latest Ratings for HCN

Sep 2015Mizuho SecuritiesMaintainsBuy
Sep 2015Evercore PartnersMaintainsBuy
Aug 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for HCN
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (HCN)

Get Benzinga's Newsletters